Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $74.68 USD
Change Today -0.04 / -0.05%
Volume 764.2K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

kythera biopharmaceuticals i (KYTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/15 - $76.31
52 Week Low
10/8/14 - $29.86
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

kythera biopharmaceuticals i (KYTH) Related Bloomberg News

View More Bloomberg News

kythera biopharmaceuticals i (KYTH) Related Businessweek News

No Related Businessweek News Found

kythera biopharmaceuticals i (KYTH) Details

KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market in the United States and internationally. Its product candidate ATX-101, is an injectable drug in late-stage clinical development for the the reduction of submental fat. The company also maintains research interest in hair and fat biology, pigmentation modulation, and facial contouring. It has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United States and Canada. The company was formerly known as AESTHERx, Inc. and changed its name to KYTHERA Biopharmaceuticals, Inc. in July, 2006. KYTHERA Biopharmaceuticals, Inc. was founded in 2004 and is headquartered in Westlake Village, California.

212 Employees
Last Reported Date: 08/6/15
Founded in 2004

kythera biopharmaceuticals i (KYTH) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $495.1K
Chief Financial Officer
Total Annual Compensation: $336.0K
Chief Medical Officer
Total Annual Compensation: $446.6K
Compensation as of Fiscal Year 2014.

kythera biopharmaceuticals i (KYTH) Key Developments

Kythera Biopharmaceuticals, Inc. Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat

KYTHERA Biopharmaceuticals, Inc. announced it has submitted a Marketing Authorization Application (MAA) in the European Union (EU), seeking approval for ATX-101 (deoxycholic acid) injection as a treatment for the reduction of submental fat when the presence of submental fat has a psychological impact for the patient. The MAA was submitted via the Decentralized Procedure with Sweden as the Reference Member State and is supported by results from four pivotal Phase III trials conducted in Europe and North America. More than 1,500 patients participated in these trials with 757 patients treated with ATX-101. Submental fullness, also referred to as double chin, is a common yet under-treated condition that can detract from an otherwise balanced and harmonious facial appearance to an older and heavier look.

Kythera Biopharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Kythera Biopharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's product sales, net were $0.29 million. Loss from operations was $35.9 million compared with $18.3 million a year ago. Net loss was $37.2 million or $1.44 per basic and diluted share compared with $19.5 million or $0.86 per basic and diluted share a year ago. The company had net cash used in operating activities of $25.3 million. For the six months, the company's product sales, net were $0.29 million. Loss from operations was $63.7 million compared with $87.2 million a year ago. Net loss was $65.97 million or $2.68 per basic and diluted share compared with $88.93 million or $4.00 per basic and diluted share a year ago.

KYTHERA Biopharmaceuticals, Inc. Announces U.S. Availability of KYBELLA

KYTHERA Biopharmaceuticals, Inc. announced the U.S. availability of KYBELLA (deoxycholic acid) injection, the first and only FDA-approved non-surgical treatment for reduction of submental fullness, a common yet under-treated aesthetic condition also known as 'double chin.' KYBELLA™ was approved in April by the U.S. Food and Drug Administration (FDA), and can now be purchased by physicians who have been trained on the safe use of KYBELLA™ and its approved indication. Training began earlier this month for KYBELLA™ physician trainers, with broader KYBELLA™ physician training programs to begin in late summer. Only physicians who have participated in a training program will be able to purchase KYBELLA™ and treat patients. KYBELLA™ will be available to trained physicians in a pack of four, 2 mL, single-patient use vials at a cost of $1,200 per pack or $300 per vial. KYBELLA™ is administered by injections into the fat under the chin, tailored to the treatment goals of the patient and their physician. In clinical trials, many patients experienced visible results in two to four treatments,i though up to six treatments may be administered. The average dose was 2-3 vials per treatment session (which equates to 4-6 mL). KYBELLA™ treatment resulted in high patient satisfaction during clinical trials. In fact, 79% of KYBELLA™-treated patients reported satisfaction with their appearance in association with their face and chin. Patients also reported improvement in the visual and emotional impact of submental fat when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt following treatment in relation to the amount of their submental fat.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KYTH:US $74.68 USD -0.04

KYTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KYTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation KYTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6,715.2x
Price/Book 13.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6,089.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYTHERA BIOPHARMACEUTICALS I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at